ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 Nuclear Energy Conference & Expo (NECX)
August 24–27, 2026
Dallas, TX|Hilton Anatole
Latest Magazine Issues
Jul 2026
Jan 2026
2026
Latest Journal Issues
Nuclear Science and Engineering
September 2026
Nuclear Technology
August 2026
Fusion Science and Technology
Latest News
Texas A&M welcomes uranium conversion research
The Texas A&M Engineering Experiment Station (TEES) has signed a research agreement with Quantum Leap Energy (QLE) “to advance and de-risk the commercial production of high-purity uranium hexafluoride (UF6).”
QLE is an Austin, Texas–based subsidiary of ASP Isotopes (ASPI), which is developing an isotope enrichment platform for applications in nuclear energy, nuclear medicine, and semiconductors. QLE specializes in the uranium conversion step of the nuclear fuel cycle—the conversion of yellowcake uranium concentrate (U3O8) into UF6 prior to enrichment.
Joetta Goda, Caiser Bravo, Theresa Cutler, Travis Grove, David Hayes, Jesson Hutchinson, George McKenzie, Alexander McSpaden, William Myers, Rene Sanchez, Jessie Walker
Nuclear Science and Engineering | Volume 195 | Number 1 | November 2021 | Pages S55-S79
Technical Paper | doi.org/10.1080/00295639.2021.1947103
Articles are hosted by Taylor and Francis Online.
The work presented in this paper focuses on the first 10 years (2011–2020) of Godiva IV operations at the National Criticality Experiments Research Center (NCERC). Godiva IV is a fast burst critical assembly constructed of approximately 65 kg of highly enriched uranium fuel alloyed with 1.5% molybdenum for strength. Godiva is one of the last such critical assemblies in the United States and can be used for studies of super-prompt-critical behavior as well as irradiations and demonstrations. An overview of the startup of Godiva IV at NCERC is given followed by a summary of the experiments performed utilizing Godiva IV over the first 10 years of operation at NCERC.